Literature DB >> 12542475

Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes.

David Bowen1, Dominic Culligan, Simon Jowitt, Stephen Kelsey, Ghulam Mufti, David Oscier, Jane Parker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12542475     DOI： 10.1046/j.1365-2141.2003.03907.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  58 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Comparison of myocardial and hepatic iron loading, assessed by MRI T2*, in patients with myelodysplastic syndromes, thalassaemia major and controls.

Authors:  Sophie Mavrogeni
Journal:  Blood Transfus       Date:  2011-12-21       Impact factor: 3.443

Review 3.  Iron chelation therapy in myelodysplastic syndromes: where do we stand?

Authors:  Mhairi Mitchell; Steven D Gore; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2013-08       Impact factor: 2.929

4.  Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach.

Authors:  Giulio Giordano; Patrizia Mondello; Rosa Tambaro; Nicola Perrotta; Fabio D'Amico; Antonietta D'Aveta; Giuseppe Berardi; Bruno Carabellese; Andrea Patriarca; Grazia Maria Corbi; Luigi DI Marzio; Antonietta Licianci; Donata Berardi; Liberato DI Lullo; Roberto DI Marco
Journal:  Mol Clin Oncol       Date:  2015-04-29

5.  Assessment of the international prognostic scoring system for determining chemotherapeutic indications in myelodysplastic syndrome: Japanese retrospective multicenter study.

Authors:  Yoshikazu Ito; Kazuma Ohyashiki; Hisamaru Hirai; Seishi Ogawa; Kinuko Mitani; Tomomitsu Hotta; Masami Bessho; Tomoki Naoe; Hideaki Mizoguchi; Takashi Uchiyama; Mitsuhiro Omine
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

6.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

7.  A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response.

Authors:  Takayuki Ishikawa; Kaoru Tohyama; Shinji Nakao; Yataro Yoshida; Masanao Teramura; Toshiko Motoji; Masaaki Takatoku; Mineo Kurokawa; Kinuko Mitani; Takashi Uchiyama; Mitsuhiro Omine
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

8.  Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study.

Authors:  Emilio Paolo Alessandrino; Matteo Giovanni Della Porta; Andrea Bacigalupo; Luca Malcovati; Emanuele Angelucci; Maria Teresa Van Lint; Michele Falda; Francesco Onida; Massimo Bernardi; Stefano Guidi; Barbarella Lucarelli; Alessandro Rambaldi; Raffaella Cerretti; Paola Marenco; Pietro Pioltelli; Cristiana Pascutto; Rosi Oneto; Laura Pirolini; Renato Fanin; Alberto Bosi
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

Review 9.  [Individualized management and therapy of myelodysplastic syndromes].

Authors:  Reinhard Stauder; Friedrich Wimazal; Thomas Nösslinger; Otto Krieger; Wolfgang R Sperr; Heinz Sill; Michael Pfeilstöcker; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

10.  Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines.

Authors:  Amy J Davidoff; Sheila R Weiss; Maria R Baer; Xuehua Ke; Franklin Hendrick; Amer Zeidan; Steven D Gore
Journal:  Leuk Res       Date:  2013-03-21       Impact factor: 3.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.